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Abstract
Objectives To assess the feasibility of a 2nd generation MR-
compatible, remote-controlled manipulator (RCM) as an aid
to perform MR-guided transrectal prostate biopsy in males
with suspicion of prostate cancer (PCa).
Methods This prospective phase I study was approved by the
local ethical committee and written informed consent was ob-
tained from each patient. Twenty patients with ≥1 cancer sus-
picious region (CSR) with a PI-RADS score of ≥3 detected on
the diagnostic multi-parametric MRI and no prior prostate
treatment underwent MR-guided biopsy with the aid of the
RCM. Complications were classified according to the modi-
fied Clavien system for reporting surgical complications. For
evaluation of the workflow, procedure- and manipulation
times were recorded.
Results All CSR’s (n=20) were reachable with the MR-
compatible RCM and the cancer detection rate was 70 %.
The median procedure time was 36:44 minutes (range, 23 –
61 minutes) and the median manipulation time for needle
guide movement was 5:48 minutes (range, 1:15 – 18:35 mi-
nutes). Two Clavien grade 1 complications were reported.
Conclusions It is feasible and safe to perform transrectal MR-
guided prostate biopsy using a MR-compatible RCM as an
aid. It is a fast and efficient way to biopsy suspicious prostate
lesions with a minimum number of biopsies per patient.
Key Points
• It is feasible to perform transrectal prostate biopsy using a
MR-compatible RCM.
• Using a RCM for MR-guided biopsy is safe, fast, and
efficient.
• All cancer suspicious regions were reachable with the RCM.
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Abbreviations
CSR Cancer suspicious region
DWI Diffusion weighted imaging
GS Gleason Score
HGPIN High-grade prostatic intraepithelial neoplasia
mpMRI Multi-parametric magnetic resonance imaging
MR Magnetic resonance
PCa Prostate cancer
PI-RADS Prostate imaging and reporting archiving
data system
PSA Prostate specific antigen
RCM Remote controlled manipulator
TrueFISP True fast imaging with steady state precession
TRUS Transrectal ultrasound
Introduction
Men with a suspicion of prostate cancer (PCa), due to an
elevated prostate specific antigen (PSA) and/or an anomalous
digital rectal examination, undergo random systematic
transrectal ultrasound (TRUS) guided biopsies to detect PCa.
However, these biopsies are affected by underscoring and
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undersampling of PCa and have relatively low detection rates
(22 – 42 %) [1–3].
Currently, multi-parametric MRI (mpMRI) is the most sen-
sitive and specific imaging technique for localizing PCa [4].
Earlier reports indicated higher detection rates for clinically
significant PCa with mpMRI and MR image-guided biopsies,
which were previously missed with systematic TRUS-guided
biopsies [5, 6]. Recently, it has been shown that MR image-
guided biopsies resulted in fewer biopsies per patient com-
pared with standard TRUS biopsy, and a decreased detection
rate of clinically insignificant cancers [7, 8].
Nevertheless, there are some limitations associated with in-
bore MR image-guided prostate biopsies. It can be time-
consuming; site-experience with mpMRI and a trained pros-
tate radiologist are needed. The majority of the procedure time
in MR-guided prostate biopsy is lost during device manipula-
tion. To facilitate correct alignment of the needle guide with
the target lesion, the patient is repeatedly moved in and out of
the MR scanner for device manipulation. To simplify and
improve the process of needle placement,MR-compatible ma-
nipulators have been developed [9, 10].
The purpose of this phase I study was to assess the feasi-
bility of a second generation MR-compatible manipulator as
an aid to perform transrectal prostate biopsy in males with




This prospective phase I study was approved by the local
ethical committee and written informed consent was obtained
from each patient. Twenty consecutive patients with at least
one cancer suspicious region (CSR) with a PI-RADS score of
≥3 detected on the diagnostic mpMRI, no prior treatment of
the prostate, and scheduled for MR-guided biopsy were in-
cluded. The most recent PI-RADS version was used [11, 12].
The mpMRI comprised T2-weighted, diffusion-weighted, and
dynamic contrast-enhanced sequences and was acquired ac-
cording the ESUR guidelines for prostate MRI [11]. The size
of the CSR was measured on the ADC map. The maximal
measured diameter was used to classify the CSRs in three
different groups: CSRs ≤10 mm, CSR’s >10 mm and
≤20 mm and CSRs >20 mm. Exclusion criteria were contra-
indications toMR imaging (e.g., cardiac pacemakers, intracra-
nial clips) and biopsy (e.g., rectal pathology).
MR-compatible manipulator
TheMR-compatible manipulator used in this study is a second
generation remote controlled manipulator (RCM) (Fig. 1)
developed by Soter ia Medical BV (Arnhem, the
Netherlands). The device is completely composed of plastic
parts and tubing, preventing distortion of the magnetic field
and enabling optimal patient safety. It is very compact, be-
cause it was designed to fit between the patient’s legs in the
restricted space of the MR bore. The RCM is driven by pneu-
matic air stepper motors allowing fast and precise steps for the
positioning of the needle guide. In combination with a stand-
alone computer and dedicated interventional software for
planning purposes and remote control, the manipulator posi-
tions the needle guide relative to the suspicious area by using
the acquired images. This combination allows for a quick
interaction to fine-tune the needle guide relative to the gland
to adjust for either patient motion or tissue obstruction. The
stand-alone computer and controller are located in the control
room next to the MR console. The major differences between
the new generation and the older version are the specifically
designed stepper motors and the dedicated software. The new
patented motor principle allows for a different geometrical
setup and, therefore, a more compact design of the
manipulator.
MR-guided biopsy procedure
All patients received antibiotic prophylaxis (oral ciprofloxa-
cin, two times a day 500 mg) during three days, starting on the
day before biopsy. The MR-guided biopsy procedures were
performed in a 3 TMR scanner (MAGNETOMTrio or Skyra,
Siemens Healthcare, Erlangen, Germany) with the MR-
compatible RCM.
Patients were positioned in a prone position on the MR
table with the RCM positioned between their legs. An MR-
compatible needle guide (Invivo, Schwerin, Germany) was
inserted in the rectum and attached to the RCM (Fig. 2). A
body phased-array coil was placed over the patient’s pelvis for
signal reception.
Fig. 1 The remote controlled manipulator (Soteria Medical, Arnhem, the
Netherlands)
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Axial T2-weighted - and diffusion weighted images
(DWI) were acquired to relocalize the CSR previously de-
tected on the diagnostic mpMRI. Directly after acquisition
of the T2-weighted and DWI sequences, the images were
sent to the standalone PC with dedicated interventional
software, for optimal positioning of the needle guide for
biopsy. The software automatically detected the needle
guide and highlighted its position with a colour overlay
on the MR images. If necessary, the rotation point of the
needle guide could be adjusted manually. Subsequently, the
radiologist planned and defined the desired target for biop-
sy. The software calculated the optimal path and the RCM
steered the needle guide towards this area. The optimal
position of the needle guide, the needle track and sample
core were represented by a blue, yellow, and red line over-
lay (Fig. 3). For verification purposes of the new position of
the needle guide, true fast imaging with steady state preces-
sion (TrueFISP) images in two directions was acquired.
If the needle guide position was not aligned correctly with
the CSR, for example due to resistance of the anal sphincter or
patient movement, the position of the needle guide was fine
tuned with the help of the software followed by new TrueFISP
images for verification. This step was repeated until the needle
guide was correctly aligned with the CSR.
Eventually, after correct alignment of the needle guide with
the CSR, a biopsy was taken. The position of the biopsy nee-
dle in situ was confirmed with TrueFISP images in the sagittal
and axial planes (Fig. 4).
Feasibility and adverse events were reported with rates and
description of adverse events. Surgical complications were
classified according to the modified Clavien system for
reporting surgical complications [13]. For evaluation of the
workflow, procedure times were recorded. The total procedure
time was defined as from the acquisition of the first localizer
to the last confirmation image with the biopsy needle in situ.
Manipulation time was determined as the time required for
needle guide positioning towards a CSR. The set-up time of
the RCM was not measured. The set-up of the RCM and its
PC were quite straightforward; the RCM was positioned on
the MR-table, and its PC was connected to the MR-computer.
This was done simultaneously with patient positioning on the
MR table and did not cost additional time.
Histopathological analyses
The biopsy specimens were subsequently fixed in 10 % buff-
ered formalin. Before being evaluated by a urogenital pathol-
ogist, the samples were embedded in paraffin, and stained
with haematoxylin-eosin, according to our standard hospital
protocol. All biopsy samples that were positive for PCa were
assigned a Gleason score (GS) according to the Gleason-
scoring system of 2005. Clinically significant PCa was de-
fined as GS ≥ 3+4, or GS 3+3with >1 positive core or a cancer
core length > 6 mm [8].
Results
In total, 20 patients were included in this study. All patient
characteristics are shown in Table 1. All CSRs were reachable
with the RCM and biopsy was performed in all patients.
Two minor complications, classified as Clavien Grade 1,
were reported. One man experienced extreme nausea and felt
the urge to move after sampling the second biopsy core. This
led to activation of the safety mechanism, which detached the
needle guide from the RCM. Two additional biopsy cores
were sampled manually. Another patient fainted directly after
the MR-guided biopsy procedure.
Procedure time
The median procedure time was 36:44 min with a range of 23
– 61 min. Median manipulation time for needle guide move-
ment was 5:48 min (range, 1:15 – 18:35 min). No additional
time was needed to set-up the RCM.
Histopathologic outcomes
A total of 20 prostate lesions with a PI-RADS score of 3 or
higher were detected in 20 patients. A median of two biopsies
per lesion (range, 2 – 4) were taken. Fourteen out of 20 lesions
(70 %) were proven to be PCa. Twelve out of 20 (60 %) were
clinically significant. Four biopsies contained prostatitis, one
contained high-grade prostatic intraepithelial neoplasia
(HGPIN) and one contained normal prostate tissue. Eleven
of the lesions were located in the peripheral zone and nine
were located in the transition zone.
Fig. 2 The remote controlled manipulator positioned between the
patient’s legs
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Discussion
MR-guided transrectal prostate biopsy with the aid of an MR-
compatible RCMwas a feasible and safe procedure. All CSRs
were reachable with the RCM and the cancer detection rate
was 70 %. The median procedure time was 36:44 min (range,
23 – 61 min) and our median manipulation time for needle
guide movement was 5:48 min (range, 1:15 – 18:35 min).
Yakar et al. described the results of the first generation MR
compatible manipulator and since then no other studies de-
scribing this procedure have been reported [9]. They reported
a median biopsy procedure time of 76.5 min (range, 45 –
105 min), a median manipulation time of 2.5 min (range, 1 –
5 min) and a cancer detection rate of 56 %. A systematic
review on transrectal MR-guided prostate biopsies, published
in 2013 by Overduin et al., found nine papers describing this
procedure in a closed bore system [14]. In these nine papers,
684 patients were biopsied with a median cancer detection rate
of 42 % (range, 8 – 59 %), and the median procedure time for
MR-guided biopsy in a closed bore setting was 55 min (range,
30 – 68 min).
Compared to our data, the main improvement is the major
decrease in total procedure time. With the current RCM, the
median procedures times were approximately 40 min and
20 min faster than with, respectively, the first generation ma-
nipulator as with the standard manual procedure. The major
goal of the development of the RCM was to speed up the
biopsy procedure and our results showed that this is possible.
However, our results might have been biased because per
patient only one CSR was biopsied. Despite the decrease in
total procedure time, the median manipulation time with the
RCM was longer than the median manipulation time of the
first-generation manipulator.
Possible explanations for this are the additional time need-
ed to transfer the data, the repeated learning curve for multiple
users as well as the built-in safety mechanism of the RCM.
When the needle guide experienced resistance during move-
ment, the RCM stopped moving. This sometimes led to extra
iterations of needle guide movement, especially for CSRs lo-
cated in the base or apex of the prostate or CSRs located very
laterally. An upgrade of the RCM software enabling adjust-
ment of the rotation point of the needle guide is expected to
improve this.
Next to this, our cancer detection rate was higher than
described in the other studies. Multiple factors may account
for this, as for example the high number of PI-RADS 5 lesions
(11/20), or it may indicate that performing targeted prostate
biopsy with our RCM is accurate. However, the real biopsy
accuracy should be examined in an additional study.
Another emerging way to perform targeted prostate biop-
sies is with MRI-TRUS fusion. Previously acquired MR im-
ages are fused with real-time TRUS images to acquire targeted
tissue samples from the suspicious area. Major advantages of
this technique are that no expensive MR scan time and MR-
compatible materials are needed when performing a biopsy,
however it does require significant investment in additional
Fig. 3 Screenshot of the planning software accompanying the remote controlled manipulator. The current position of the needle guide is represented by
the orange line, the desired position for biopsy, the needle track and sample core are represented by the blue, yellow and red line, respectively
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equipment. A recently published review on this subject found
a median cancer detection rate of 50.5 % (range, 23.7 – 82.1)
in a total of 2293 patients [15]. Procedure times were not
reported. This was done by Brock et al., who performed two
targeted fusion guided biopsies in 52 patients and found a
mean biopsy procedure time of 15 min (range, 8 – 49 mins);
however their detection rate was only 26.4 % [16].
Comparison with manual MR-guided biopsy is difficult, be-
cause in most papers more than one lesion is targeted and the
time per lesion is barely specified. In theory, it may turn out
that MRI-TRUS fusion biopsy is especially suitable for pa-
tients with large, high-grade PCa lesions, because these are
often better visible on ultrasound. In our opinion, in-boreMR-
guided biopsy is more preferable for the smaller lesions.
However, direct comparison with prospective randomized
controlled trials between MRI-TRUS fusion biopsy and in-
bore MR-guided biopsy are needed to find out which tech-
nique is the most appropriate to detect PCa. Recently, Arsov
et al. published the results of a randomized study investigating
the detection rate of MR-guided in bore biopsy versus the
combined approach of MRI-TRUS fusion biopsy with
systematic TRUS biopsy [17]. No significant difference was
found between both groups.
Our study had a number of limitations. The RCM and its
software were continuously optimized during this study.
However, this is inherent to the natural process of a feasibility
study. The most significant adjustments were the introduction
of a direct connection between the MR console and the
standalone RCM PC to sendMR images, and the introduction
of the software option to adjust the rotation point of the needle
guide. It is expected that these adjustments will even lead to a
further decrease of the manipulation and procedure time.
Another limitation of this study was the relatively small pa-
tient population.
The next step is to examine the biopsy accuracy of the
RCM. For further studies, the application of the RCM in com-
bination with an automated real-time needle-guide tracking
sequence [18], or during MR-guided transrectal targeted ther-
apies, as for instance focal laser ablation, can be investigated
[19]. With some minor adjustments, the RCM may also be
used during transperineal prostate biopsies and targeted ther-
apies, as for example MR-guided cryoablation [20].
Fig. 4 MR images of a 68-year-
old patient, PSA 10.1 ng/mL and
three negative TRUS biopsy
sessions. A+B:MP-MRI showed
a PI-RADS 5 lesion (yellow
circle) in the right peripheral zone
of the apex of the prostate. C+D :
TrueFisp images in two directions
acquired with the biopsy needle in
situ. Histopathologic analyses
showed a GS 3+4=7, cancer core
length 7 mm
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Conclusion
It is feasible to perform transrectal MR-guided prostate biopsy
using a remote controlled, MR-compatible, manipulator as an
aid. It is a fast, and, therefore, efficient way to biopsy suspi-
cious prostate lesions with a minimum number of biopsies per
patient.
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